Ivermectin + Fenbendazole Protocols for remission, aggressive cancer, and poor prognosis

Share

Share

Share

Share

Email

Comments

🔹 A powerful protocol below using Ivermectin + Fenbendazole for remission, aggressive cancer, and poor prognosis from X.

Oncologist Dr. William Makis:

“Antiparasitics have a dozen mechanisms of action… by which they act on cancer… ivermectin… goes after cancer stem cells… fenbendazole and mebendazole… shut down glucose transporters… [preventing] the cancer cell from taking up glucose and using it as a fuel source.”

—————-Partial transcription of clip—————

“Antiparasitics really have a dozen mechanisms of action. Each of them has a dozen mechanisms of action by which they act on cancer. They act on cancer at the cellular level. They change the cell. They change, you know, some of the genetic expression of the cell. So they shut down certain things that the tumor cell produces. It’s really, really fascinating.

“For ivermectin, it really goes after cancer stem cells. And this is where it is a beautiful addition to chemo, because chemo will kill rapidly dividing cells. So it kills, let’s say, 90, 95% of the tumor cells that are rapidly dividing. But cancer stem cells don’t rapidly divide. But that’s not their nature. They sit in the tumor and they wait, and they might start dividing five years from now, 10 years from now, and they spread to other parts of the body. And that’s why chemo is not curative in 98% of the cases.

“They will always tell you chemo’s palliative, not curative. Those are keywords….By the way, when the oncologist tells you palliative versus curative, those are keywords to tell you we can’t cure you with chemo. And they know why. Because they can’t kill the cancer stem cells.

“And so ivermectin can actually go in and kill those cancer stem cells. That’s something that chemo is not capable of doing. That’s why we’re seeing results with chemo plus ivermectin that oncologists have never seen, because they have never seen cancer cell killing. That is so good. And tumor shrinkage that is so dramatic. When you add the ivermectin, you’re targeting, the cancer stem cells. So that is a fascinating feature of ivermectin.

“Another feature of ivermectin is it’s able to reverse resistance to chemo that cancer cells develop. And so ivermectin will go in and it’ll actually change the cancer cells from being able to pump chemo out of them. And now they’re chemo resistant. It actually removes the ability of cancer cells to do that. It inhibits those pumps that pump the chemo back out. Now the tumor cell is susceptible to chemo again. The patient gets chemo, and the cancer cells are all killed.

“So again, these are just two of the dozen mechanisms that researchers have found. And this has all been proven in preclinical research. That’s why there’s over 400 papers on ivermectin and cancer, not because it’s something that’s, you know, it’s a fad or something curious. They’ve studied the molecular mechanisms of how ivermectin is attacking cancer. And this is where, you know, a lot of doctors who make fun of ivermectin or who attack ivermectin, this is really where they show their ignorance of the research. These 400 papers, most of them published in the last five years, that go into the mechanisms of how ivermectin is doing this.

“And same with fenbendazole and mebendazole. An example, quick example is fenbendazole and mebendazole, also antiparasitics. They kill different types of worms, and parasites than ivermectin does. They shut down glucose transporters on cancer cells, so they prevent the cancer cell from taking up glucose and using it as a fuel source.

“This is one of the major ways by which tumors grow. When they have access to sugar, they use it as fuel. And then you have these rapidly dividing cells that have plenty of fuel to grow. So they shut down tumor growth by shutting down these glucose transporters. So that’s a fascinating mechanism. Again, you don’t see that with any type of chemo, any type of immunotherapy. There’s no other drug, fancy drug on the market that does that.”

---

Dr. William Makis MD – Cancer Protocol

A powerful protocol below using Ivermectin + Fenbendazole for remission, aggressive cancer, and poor prognosis.

📌 Ivermectin

– 0.5–2.5mg/kg/day based on cancer severity
– Proven results: prostate, ovarian, gallbladder, brain cancer
– No long-term side effects (even at high doses)

📌 Fenbendazole

– 222–1000mg/day (6 days/week)
– Add: CBD, Curcumin, Milk Thistle
– Supports liver/kidney health

You may also find this Cancer Protocol Useful

Week 1 (6 days on, 1 day off):

Fenbendazole — 2 Grams
Ivermectin — 1 mg/kg of body weight
Milk Thistle — 500 mg
CBD — 100 mg
Black Seed Oil — 1 teaspoon

Week 2 (6 days on, 1 day off):

Fenbendazole — 3 Grams
Ivermectin — 1 mg/kg of body weight
Milk Thistle — 500 mg
CBD — 100 mg
Black Seed Oil — 2 teaspoons

Week 3 (6 days on, 1 day off):

Fenbendazole — 4 Grams
Ivermectin — 1 mg/kg of body weight
Milk Thistle — 500 mg
CBD — 100 mg
Black Seed Oil — 3 teaspoons

Repeat Week 3 until cancer gone

Side effects may include laxative effects (fenben) and blurry vision (ivermectin).
Stay at lower doses until these pass.
Take Ivermectin and Fenbendazole with fatty foods.

---

---

🔹 Notes on Evidence & Safety

1. Evidence Levels
   • Preclinical = cell or animal studies only
   • Anecdotal = isolated case reports, no controlled trials
   • Moderate = some human clinical data, mostly supportive, not curative
2. Risk Assessment
   • Ivermectin & Fenbendazole carry higher systemic risk at experimental doses.
   • Nutraceuticals (milk thistle, black seed, curcumin, CBD) are low-risk, mainly GI or mild drug interactions.
3. Framework for Analysis
   • Categorize by primary vs supportive
   • Track mechanism, claimed effect, human evidence, and risk
   • Can be extended with observed adverse events and research references

---

Category	Substance	Claimed Use / Mechanism	Dose Range (from online protocols)	Evidence Strength	Risk / Safety Notes
Primary Antiparasitic / Experimental Anticancer	Ivermectin	Inhibits importin α/β → anti-proliferative, apoptosis induction	0.5–2.5 mg/kg/day (based on severity, anecdotal)	Preclinical + small case reports	Neurotoxicity at high doses; limited human oncology evidence
Primary Antiparasitic / Experimental Anticancer	Fenbendazole	Microtubule inhibition → cell cycle disruption	222–1000 mg/day (6 days/week)	Animal models; anecdotal human cases	Hepatotoxicity potential at high dose; not approved for human cancer therapy
Hepatoprotective / Detox Support	Milk Thistle (Silymarin)	Antioxidant, liver enzyme stabilization	140–420 mg/day	Moderate: human liver studies	Generally safe; mild GI upset possible
Hepatoprotective / Detox Support	Black Seed Oil (Nigella sativa)	Anti-inflammatory, antioxidant	1–3 g/day	Limited: mostly preclinical	Allergic reactions rare; human oncology data lacking
Anti-inflammatory / Signaling Modulators	Curcumin / Turmeric	NF-κB modulation, anti-inflammatory	500–2000 mg/day (with fat for absorption)	Moderate (mostly adjunct in trials)	Low toxicity; absorption variable
Anti-inflammatory / Signaling Modulators	CBD (Cannabidiol)	Modulates inflammation, pain	10–50 mg/day (anecdotal)	Limited human cancer studies	Mild sedation, GI upset; drug interactions
Bioavailability / Absorption Enhancers	Fatty meals / oils	Improve absorption of lipophilic compounds	N/A	Established pharmacology	Safe